1. Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B

3. Introduction/Overview

4. Introduction/Overview (cont)

5. Importance of Prophylaxis, and Limitations on Its Application, in Hemophilia B

6. Key Unmet Need in Hemophilia B: Reducing Patient Burden of Disease

7. Improving Adherence in Hemophilia B

8. Potential Barriers to Adherence in Hemophilia Prophylaxis

9. Improving Adherence by Addressing the Barriers to Prophylaxis

11. Surgical Experience With EHL rFIX Replacement Therapy

12. Annualized Bleeding Rates: Results From the B-LONG Study

13. Inhibitor Development in EHL Molecules for Treatment of Hemophilia B

15. Annualized Bleeding Rates: Results From the Nonacog Beta Pegol Phase 3 Trial

16. The Importance of Maintaining Trough Levels to Prevent Breakthrough Bleeding

17. EHL Agents and Treatment Individualization

18. rFIX-FP Phase 3 Study in Hemophilia B: Study Design

19. rFIX-FP Phase 3 Study: AsBRs of Prophylaxis Patients

20. rFIX-FP Phase 3 Study: Safety Results

21. EHL Agents and Treatment Individualization

22. Phenotypic Variability Among PWH

23. Pharmacokinetic Characteristics of 3 EHL Agents

24. Evolution of FVIII/FIX Concentrates

25. Case Studies With Long-Acting FIX Therapies

26. Introduction/Overview

27. Case 1: 30-Year-Old Man Typically Treated on Demand

28. Case 2: Older Man With a Sedentary Lifestyle

29. Case 3: Patient Requiring Surgery

30. Case 4: Patient With a Frequent Bleeding Phenotype

31. Summary and Conclusions

32. Hemophilia B Treatment Goals

33. The Benefits of EHL Therapies in Hemophilia B

34. Transforming the Treatment Paradigm

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)